Kanıt: Klinik çalışmalarda ZYTIGA

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Kanıt: Klinik çalışmalarda ZYTIGA"

Transcription

1 mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya

2 Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen Receptor inhibitors: -Bicalutamide -MDV 31 -ODM-21 -ARN 59 Castration (alhrh or Surg.) Testosterone Autocrine secretion Abiraterone Orteronel DNA Cell division

3 b Abiraterone: CYP17 blockade inhibits androgen synthesis

4

5

6 COU-AA-31: Abiraterone acetate Phase III post-chemotherapy 1195 patients with progressive mcrpc Failed 1 or 2 chemotherapy regimens, 1 of which contained docetaxel R A N D O M I Z E D 2:1 Abiraterone 1mg daily Prednisone 5mg BID n=797 Placebo daily Prednisone 5mg BID n=398 Efficacy end points (ITT) Primary end point: OS (25% improvement; HR.8) Secondary end points: TTPP rpfs PSA response FACT-P questionnaire Prospective data collection: Day 1 of Cycles 1, 4, 7, 1, and every 6 cycles thereafter until the end of study treatment Stratification by: ECOG performance status -1 vs 2 Worst pain over previous 24 hours BPI short form; -3 (absent) vs 4-1 (present) Prior chemotherapy 1 vs 2 Type of progression PSA only vs radiographic with or without PSA BPI, Brief Pain Inventory; HR, hazard ratio; ITT, intent to treat; TTPP, time to PSA progression; rpfs, radiographic progression-free survival; PSA, prostate-specific antigen Fizazi et al. Lancet Oncology 212 3(1): Harland et al. Eur J Cancer 213 Aug 22. pii: S (13)72-X. doi: 1.116/j.ejca [Epub ahead of print]

7 COU-AA-31 Baseline Demographics Abiraterone (n=797) Placebo (n=398) Total (n=1195) Median age, years (range) 69. (42-95) 69. (39-9) 69. (39-95) Race, % White Black Asian ECOG PS 2, % Significant pain present, % Prior chemotherapies, %

8 Extent of disease Baseline Disease Characteristics Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) Bone 89% 9% Node 45% 41% Liver 11% 8% Lung 13% 11% Other Visceral 6% 5% Prostate mass 8% 6% Other tissue 5% 5% Viscera, NOS.1% PSA (median, ng/ml) ( ) ( ) Hemoglobin (median, g/dl) LDH (median, IU/L) de Bono et al. N Engl J Med 211; 346(21): de Bono et al. N Engl J Med 211; 346(21): (Supplementary Data)

9 Baseline Disease Characteristics Gleason score at initial diagnosis Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) % 46.% % 54.% PSA at initial diagnosis (ng/ml) Median (range) 27 ( ) 35.5 ( ) Previous cancer therapy Surgery 54% 49% Radiotherapy 72% 72% Hormonal 1% 1% Other* 1% 1% * Includes chemotherapy de Bono et al. N Engl J Med 211; 346(21): de Bono et al. N Engl J Med 211; 346(21): (Supplementary Data)

10

11 Survival Benefit Observed With AA Is Consistent For Majority of Subgroups Fizazi et al, abstr #7, ECCO 211

12 Survival (%) Survival (%) Survival by Baseline ECOG Status Favors AA for ECOG -1, but not for ECOG 2; May be Attributed by the Small Sample Size ECOG -1 ECOG 2 (1% of patients) Abiraterone + prednisone: 17 months 8 Abiraterone + prednisone: 7.3 months Placebo + Prednisone: 12.3 months 4 2 Placebo + prednisone: 7 months Time to Death (Months) Time to Death (Months) Median OS Abiraterone + prednisone vs. Placebo + prednisone ECOG -1: 17 vs months (HR=.74; 95% CI: ; p=.2) ECOG 2: 7.3 vs. 7 months (HR=.77; 95% CI: ; p=.2166) Fizazi et al. Lancet Oncol 212; 13(1): (Supplementary Appendix)

13 Survival (%) Survival (%) Survival (%) Survival Benefit Observed With AA Across All Age Groups < 65 Years 65 Years 75 Years Abiraterone + prednisone : 15. months 8 6 Abiraterone + prednisone : 16.2 months 8 6 Abiraterone + prednisone : 15.6 months 4 2 Placebo + prednisone : 11.2 months 4 2 Placebo + prednisone : 11.1 months 4 2 Placebo + prednisone : 9.3 months Time to Death (Months) Time to Death (Months) Median 22 OS Abiraterone prednisone vs. Placebo 6 + prednisone: < 65 years: 15. vs months (HR=.69; 95% CI: ) 65 years: 16.2 vs months (HR=.76; 95% CI:.63-.9) 75 years: 15.6 vs. 9.3 months (HR=.64; 95% CI: ) Time to Death (Months) Fizazi et al. ECCO 211: Abstract 7 (oral presentation)

14 Survival (%) Survival (%) Survival Benefit Observed With AA for Subgroups With and Without Visceral Disease at Study Entry Without Visceral Disease With Visceral Disease Abiraterone + prednisone : 17.1 months 8 Abiraterone + prednisone : 12.9 months Placebo + prednisone : 12.3 months 4 2 Placebo + prednisone : 8.3 months Time to Death (Months) Median OS Abiraterone + prednisone vs. Placebo + prednisone: Without visceral disease: 17.1 vs months (HR =.69; 95% CI: ) With visceral disease: 12.9 vs. 8.3 months (HR =.79; 95% CI: ) Time to Death (Months) Fizazi et al. ECCO 211: Abstract 7 (oral presentation)

15 All Secondary End Points Achieved Statistical Significance Abiraterone + Prednisone (n = 797) Placebo + Prednisone (n = 398) HR 95% CI TTPP (months) (.46,.73) rpfs (months) (.58,.78) P Value <.1 <.1 PSA response rate Total 38.% 1.1% - <.1 Confirmed 29.1% 5.5% - <.1 Objective response (RECIST) 14.% 2.8% - <.1 de Bono et al. N Engl J Med 211; 346(21):

16 PSA Response Rate (%) Fizazi et al. ECCO 211: Abstract 7 (oral presentation) Fizazi et al. Lancet Oncol 212; 13(1): Total and Confirmed PSA Response Rates Were Significantly Higher With AA p <.1 p <.1 Total Confirmed Abiraterone + prednisone Placebo + prednisone

17 COU-AA-31: Similar AE incidence rates were observed in both groups* Abiraterone + Prednisone (n=791) All Grades Grades 3/4 Placebo + Prednisone (n=394) All Grades Grades 3/4 All AEs 99% 6% 99% 61% Serious AEs 42% 36% 44% 38% AEs leading to discontinuation 21% 11% 24% 14% AEs leading to death 13% 16% *Grade 1 or 2 urinary tract infections were higher with abiraterone compared with placebo: 12% vs 7%, p=.2 AE, adverse event. Fizazi et al. Lancet Oncology 212 3(1): de Bono et al. New Eng J Med 211; 364:

18 COU-AA-31: AEs of special interest Fluid retention and edema Abiraterone + Prednisone (n=791) All Grades Grade 3 Grade 4 Placebo + Prednisone (n=394) All Grades Grade 3 Grade 4 31% 2% <1% 22% 1% Hypokalemia 17% 3% <1% 8% 1% Cardiac disorders 13% 3% 1% 11% 2% <1% LFT abnormalities 1% 3% <1% 8% 3% <1% Hypertension 1% 1% 8% <1% Fizazi et al. Lancet Oncology 212 3(1): de Bono et al. New Eng J Med 211; 364:

19

20

21

22 Gleason skoru prediktif değil Abiraterone ile klinik yararlanım Gleason skorundan bağımsız

23

24 Pain Intensity Abiraterone + Prednisone (n=797) Placebo + Prednisone (n=398) P Value HR (95% CI) Palliation rate 45% (157/349) 28.8% (47/163).5 - Time to palliation (median) Time to progression (25 th percentile) 5.6 months 13.7 months months 4.7 months ( ).717 ( ) Duration of palliation (median) 4.2 months 2.1 months.56 - Logothetis et al. Lancet Oncol 212: 212; 13:

25 Symptomatic Improvement Pain Interference AA (n = 797) Placebo (n = 398) P Value Palliation, n (%) 132/223 (59.2) 38/1 (38.).4 Time to palliation (months) Median (95% CI) 1.2 ( ) 3.71 ( ).9 Time to progression (months) 25 th percentile (95% CI) 9.27 ( ) 4.57 ( ).19

26 Overall survival Outcomes AA (n = 797) Placebo (n = 398) P Value Median, months <.1 PSA response rate Total 38.% 1.1% <.1 Confirmed 29.1% 5.5% <.1 Radiographic PFS Median, months <.1 Time to first SRE (pathologic fracture/spinal cord compression/ palliative radiation/bone surgery) 25 th percentile, days <.1 Logothetis et al Lancet Oncol 211

27 Patients With Improvement (%) AA Was Associated With Higher FACT-P Responses Abiraterone + prednisone (n = 797) * * p =.284 Placebo + prednisone (n = 398) * * * * p <.1 p < Harland et al. ECCO 211: Abstract 71 (oral presentation)

28 Median time to decline (days) AA Delayed Time to Deterioration of QoL Abiraterone + prednisone (n=797) Placebo + prednisone (n=398) * * * * * * p<.1 * P=.325 * Harland et al. ECCO 211: Abstract 71 (oral presentation)

29 COU-AA-31 Conclusions Abiraterone acetate prolonged OS in patients with mcrpc who have progressed after docetaxel-based chemotherapy Median OS improvement of approximately 5 months 36% improvement in median survival 35% risk reduction of death (HR =.65) Improved TTPP, PFS, and PSA response rate 38% of patients had a >5% reduction in PSA Clinical benefit for treatment of bone metastases: Improved pain palliation Delayed pain progression and time to SRE Effect sustained over treatment cycles Favorable Safety Profile

30

31 Tumor volume & activity Prostate cancer drug development Chemotherapy NOTE: This diagram represents typical disease progression. Some patients are metastatic at diagnosis and are thus still castrate Castration sensitive. Abiraterone Acetate Sipeuleucel-T Docetaxel Abiraterone Acetate Cabazitaxel Alpharadin Enzalutamide

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia Meet Mr. S 74 M admitted for back pain X-ray: sclerotic lesions along spine PSA 800 Nuclear Medicine Bone Scan 1

More information

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Traitement médical du Cancer de la Prostate: du désert à la profusion Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for:

More information

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni METASTATIC PROSTATE CANCER DIFFERENT THERAPEUTIC APPROACHES Metastatic

More information

What s new in prostate cancer research? Highlights of GU-ASCO 2014

What s new in prostate cancer research? Highlights of GU-ASCO 2014 review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract

More information

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways

More information

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment Abstract Prostate is one of the most commonly diagnosed solid tumours in males worldwide. Selection of

More information

Prostate Cancer Teaching Session. Dr Anthony Joshua Kinghorn Cancer Centre St Vincents Hospital, Sydney

Prostate Cancer Teaching Session. Dr Anthony Joshua Kinghorn Cancer Centre St Vincents Hospital, Sydney Prostate Cancer Teaching Session Dr Anthony Joshua Kinghorn Cancer Centre St Vincents Hospital, Sydney Tumor Volume & Activity Natural History of Prostate Cancer Hormone-Sensitive Castrate-Resistant Surgery

More information

First-line Hormone Therapy

First-line Hormone Therapy First-line Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised

More information

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015. Updates in Prostate Cancer Therapy Sequencing Strategies Debates and Didactics in Hematology and Oncology July 26, 2015. Sea Island, GA Bradley C. Carthon, MD. Ph.D. Assistant Professor, Winship Cancer

More information

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Before, Frank's immune cells could

Before, Frank's immune cells could Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years

More information

Establishing an Advanced Prostate Cancer Clinic: The Rationale

Establishing an Advanced Prostate Cancer Clinic: The Rationale The information, views and opinions expressed in this presentation and any accompanying materials are those of the speaker and do not necessarily reflect the views or position of Cardinal Health or VitalSource.

More information

Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings

Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings A Review of Selected Presentations From the 2014 American Urological Association Meeting, May 16-21, 2014, Orlando, Florida and

More information

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou

More information

Second line. Elena Verzoni Oncologia Medica Fondazione IRCCS Istituto Nazionale Tumori Milano

Second line. Elena Verzoni Oncologia Medica Fondazione IRCCS Istituto Nazionale Tumori Milano mcrpc: First and Second line Elena Verzoni Oncologia Medica Fondazione IRCCS Istituto Nazionale Tumori Milano Landmarks of disease progression in CRPC 2-10 years 30 months Failed localized therapy Hormonal

More information

Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks

Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks Laurence Klotz Professor of Surgery Sunnybrook Health Sciences Centre University of Toronto Advantages of intermittent ADT Likely:

More information

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Please see Important Safety Information throughout this presentation and full Prescribing Information available at this 2014 Bayer

More information

American Urological Association (AUA) Guideline

American Urological Association (AUA) Guideline 1 Approved by the AUA Board of Directors April 2015 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2015 by the American Urological

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta376

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta376 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta376 NICE 2016. All rights reserved.

More information

Prostate Cancer Studies

Prostate Cancer Studies Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic

More information

Clinical Spotlight in Breast Cancer

Clinical Spotlight in Breast Cancer 2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD PROSTATE CANCER UPDATE DISCLOSURES I, BRUCE WAYNE PORTERFIELD HAVE NOTHING TO DISCLOSE. OBJECTIVES Epidemiology Early detection and screening Review of clinical disease states Treatment options by disease

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE Summary of Presentations from the Bayer Healthcare Symposium, held at the 29 th Annual EAU

More information

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute Prostate Cancer Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute 1 Educational Objectives By the end of this session, participants should be able to Understand

More information

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14 MEDIVATION, INC. FORM 8-K (Current report filing) Filed 1/31/14 for the Period Ending 1/28/14 Address 525 MARKET STREET 36TH FLOOR SAN FRANCISCO, CA 9415 Telephone 415-543-347 CIK 111835 Symbol MDVN SIC

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

Therapy in Prostate Cancer: Cure or Regression

Therapy in Prostate Cancer: Cure or Regression Therapy in Prostate Cancer: Cure or Regression F. Di Silverio Department of Urologia U Bracci University La Sapienza Rome Objectives and classification of the results obtained from therapies in oncology

More information

Nuove terapie post-adt nel Carcinoma Prostatico Metastatico Resistente alla Castrazione!! Hot topics nella pratica clinica!

Nuove terapie post-adt nel Carcinoma Prostatico Metastatico Resistente alla Castrazione!! Hot topics nella pratica clinica! Nuove terapie post-adt nel Carcinoma Prostatico Metastatico Resistente alla Castrazione!! Hot topics nella pratica clinica! Beatrice Detti. Radioterapia Oncologica, AOU Careggi, Firenze. Europe: estimated

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Metastatic prostate cancer

Metastatic prostate cancer Metastatic prostate cancer Dr Alison Tree Consultant Clinical Oncologist Royal Marsden Hospital 2 Outline of the talk Metastatic prostate cancer scope Castration sensitive disease Castration resistant

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Treatment of metastatic prostate cancer CLARE GILSON, THUBEENA MANICKAVASAGAR AND SIMON CHOWDHURY

Treatment of metastatic prostate cancer CLARE GILSON, THUBEENA MANICKAVASAGAR AND SIMON CHOWDHURY 7 Treatment of metastatic prostate cancer CLE GILSON, THUBEENA MANICKAVASAG AND SIMON CHOWDHURY The authors review the current therapeutic approaches and consider the many remaining questions and challenges

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab. Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous

More information

Prise en charge du Cancer de Prostate métastatique résistant à la castration : stratégies thérapeutiques et perspectives

Prise en charge du Cancer de Prostate métastatique résistant à la castration : stratégies thérapeutiques et perspectives Prise en charge du Cancer de Prostate métastatique résistant à la castration : stratégies thérapeutiques et perspectives Dr Christophe Massard, Institut Gustave Roussy Dr Sylvestre Le Moulec, H.I.A. du

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): November 25, 2014 Effective Date: February 1, 2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS

More information

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic

More information

STATE-OF-THE-ART TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER

STATE-OF-THE-ART TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER STATE-OF-THE-ART TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER *Elena Castro, 1,2 Nuria Romero, 1,2 David Olmos 1,2 1. Prostate Cancer and Genitourinary Tumours Unit, Clinical Research Programme, Spanish

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative. Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean

More information

Advances in Prostate Cancer (Localized to Newly metastatic) Christopher Sweeney, MBBS Dana Farber Cancer Institute

Advances in Prostate Cancer (Localized to Newly metastatic) Christopher Sweeney, MBBS Dana Farber Cancer Institute Advances in Prostate Cancer (Localized to Newly metastatic) Christopher Sweeney, MBBS Dana Farber Cancer Institute Prostate Cancer: A Diseases with Many States Organ Confined Low Risk Clinically Localized

More information

A) CLINICAL TRIAL IDENTIFICATION

A) CLINICAL TRIAL IDENTIFICATION SYNOPSIS PROTOCOL GETUG-AFU 21 - UC-0160/1105 A) CLINICAL TRIAL IDENTIFICATION SPONSOR - PROTOCOL CODE NUMBER: GETUG-AFU 21 - UC-0160/1105 EUDRACT N : 2012-000142-35 VERSION AND DATE: VERSION 2.0 - JUN

More information

PROSTATE CANCER. Learning Objectives. Question 4/3/2014

PROSTATE CANCER. Learning Objectives. Question 4/3/2014 PROSTATE CANCER Lindsay Kaster, PharmD Clinical Oncology Pharmacist Boise VA Medical Center Learning Objectives Discuss the cancer diagnosis and screening, including the role of Prostate Specific Antigen

More information

Horizon Scanning in Oncology

Horizon Scanning in Oncology Horizon Scanning in Oncology Abiraterone acetate (ZytigaTM) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy Vienna, November 2011 Horizon

More information

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada Dragomir et al. BMC Health Services Research 2014, 14:252 RESEARCH ARTICLE Drug costs in the management of metastatic castration-resistant prostate cancer in Canada Alice Dragomir 1,2*, Daniela Dinea 1,3,

More information

TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER

TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE RECEIVES U.S. FDA APPROVAL FOR USE IN ADVANCED STOMACH CANCER TAXOTERE -based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer Bridgewater,

More information

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012

LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR)

CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR) CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR) This late-breaking abstract was presented on 26 th September 215 in Presidential

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

NCCN Prostate Cancer Guidelines Update. James L. Mohler, MD Roswell Park Cancer Institute

NCCN Prostate Cancer Guidelines Update. James L. Mohler, MD Roswell Park Cancer Institute NCCN Prostate Cancer Guidelines Update James L. Mohler, MD Roswell Park Cancer Institute Every 2.5 Minutes an American is Diagnosed with Prostate Cancer Every 15 Minutes an American Dies of Prostate Cancer

More information

Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine

Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine Novel Radionuclide Therapies in Oncology : Promising Area in the Field of Nuclear Medicine Erik Mittra, MD, PhD Clinical Assistant Professor Radiology / Nuclear Medicine Objectives / Outline 1. Understand

More information

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Treatment: What s Best for You? Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.

More information

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa

Use Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.

Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D. Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this

More information

REVIEW. Introduction. Key Words: prostatic cancer, biochemical recurrence, salvage radiotherapy, androgen deprivation therapy, systemic therapy

REVIEW. Introduction. Key Words: prostatic cancer, biochemical recurrence, salvage radiotherapy, androgen deprivation therapy, systemic therapy REVIEW Therapeutic options for a rising PSA after radical prostatectomy Bradley C. Carthon, MD, 1,2 David M. Marcus, MD, 2,3 Lindsey A. Herrel, MD, 4 Ashesh B. Jani, MD, 2,3,4 Peter J. Rossi, MD, 2,3,4

More information

February 8, 2012. BLA 125320/28 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT

February 8, 2012. BLA 125320/28 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT FDA ODAC Briefing Document February 8, 2012 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for

More information

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology

Oncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in

More information

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical

More information

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional

More information

Current management of advanced and castration resistant prostate cancer Leonard G. Gomella, MD, 1 Daniel P. Petrylak, MD, 2 Bobby Shayegan, MD 3 1

Current management of advanced and castration resistant prostate cancer Leonard G. Gomella, MD, 1 Daniel P. Petrylak, MD, 2 Bobby Shayegan, MD 3 1 INTRODUCTION Current management of advanced and castration resistant prostate cancer Leonard G. Gomella, MD, 1 Daniel P. Petrylak, MD, 2 Bobby Shayegan, MD 3 1 Department of Urology Kimmel Cancer Center,

More information

Metastatic Cancer: Questions and Answers. Key Points

Metastatic Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Metastatic Cancer: Questions

More information

DRUG NAME: Abiraterone

DRUG NAME: Abiraterone DRUG NAME: Abiraterone SYNONYM(S): abiraterone acetate 1 COMMON TRADE NAME(S): ZYTIGA CLASSIFICATION: endocrine anti-hormone Special pediatric considerations are noted when applicable, otherwise adult

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven

More information

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) Original cua guidelines research The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) Fred Saad, MD, FRCSC; * Kim N. Chi, MD, FRCPC; Antonio Finelli, MD, FRCSC;

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD

2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD 2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL Howard R. Soule, PhD 1 May 29-June 2, 2015 Chicago, IL Theme: Illumination and Innovation Transforming Data Into Learning We

More information

Prostate Cancer Screening

Prostate Cancer Screening Prostate Cancer Screening Bruce L. Houghton, MD Associate Professor of Medicine Division of General Medicine Department of Internal Medicine Creighton University School of Medicine http://en.wikipedia.org/wiki/image:prostatelead.jpg

More information

SRO Tutorial: Prostate Cancer Treatment Options

SRO Tutorial: Prostate Cancer Treatment Options SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,

More information

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust Louisa Fleure Advanced Prostate Cancer Clinical Nurse Specialist Guys and St Thomas NHS Trust The classification of advanced prostate cancer The incidence of patients presenting with, or developing advanced

More information

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients? Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents William Tyor, M.D. Chief, Neurology Atlanta VA Medical Center Professor, Department of Neurology Emory University School of Medicine

More information

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals

Chirurgie des métastases cérébrales. Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals Chirurgie des métastases cérébrales Dr Mark Dexter Head, Department of Neurosurgery The Westmead Hospitals The Westmead patient population THE INCONVENIENT TRUTHS Cerebral metastases occur in 10 16 % of

More information

PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:

PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS: 1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Advances in the Management of Prostate Cancer: Highlights from the 2014 ASCO Annual Meeting

Advances in the Management of Prostate Cancer: Highlights from the 2014 ASCO Annual Meeting An Interactive PDF Newsletter Advances in the Management of Prostate Cancer: Highlights from the 2014 ASCO Annual Meeting Editors Robert Dreicer, MD, MS, FACP, FASCO Chairman, Department of Solid Tumor

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy The new england journal of medicine original article in Metastatic Prostate Cancer before Chemotherapy T.M. Beer, A.J. Armstrong, D.E. Rathkopf, Y. Loriot, C.N. Sternberg, C.S. Higano, P. Iversen, S. Bhattacharya,

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information